Valneva (VALN) Projected to Post Earnings on Thursday

Valneva (NASDAQ:VALN) is anticipated to issue its Q3 2025 results before the market opens on Thursday, November 20th. Analysts expect the company to announce earnings of ($0.30) per share for the quarter. Individuals may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, November 20, 2025 at 2:00 AM ET.

Valneva (NASDAQ:VALN) last issued its earnings results on Tuesday, August 12th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.11. The company had revenue of $54.84 million for the quarter, compared to the consensus estimate of $46.28 million. Valneva had a negative net margin of 33.87% and a negative return on equity of 34.78%. On average, analysts expect Valneva to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Valneva Stock Performance

NASDAQ VALN opened at $9.19 on Thursday. The stock has a market cap of $790.16 million, a PE ratio of -9.38 and a beta of 1.83. Valneva has a twelve month low of $3.62 and a twelve month high of $12.25. The stock has a fifty day simple moving average of $9.80 and a 200-day simple moving average of $8.07. The company has a current ratio of 2.27, a quick ratio of 1.77 and a debt-to-equity ratio of 0.66.

Institutional Trading of Valneva

A hedge fund recently bought a new stake in Valneva stock. Marex Group plc purchased a new position in shares of Valneva SE Sponsored ADR (NASDAQ:VALN) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 11,300 shares of the company’s stock, valued at approximately $64,000. Hedge funds and other institutional investors own 11.39% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Valneva in a research note on Wednesday, October 8th. Jefferies Financial Group set a $14.00 target price on Valneva and gave the company a “buy” rating in a report on Monday, August 25th. Wall Street Zen upgraded shares of Valneva to a “hold” rating in a research note on Saturday, September 6th. Guggenheim decreased their price target on Valneva from $14.00 to $13.00 and set a “buy” rating for the company in a report on Monday, September 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Valneva in a report on Monday, August 25th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $15.00.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.